At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...
Precision BioSciences is dedicated to improving...
We are a commercial-stage biotech company focused on harnessing the inherent biolo...
We are a commercial-stage biotech company focus...
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to provi...
Accelerate Diagnostics, Inc. is an in vitro dia...
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
Join the National Investor Network and get the latest information with your interests in mind.